|
|
Blood, 1 July 2008, Vol. 112, No. 1, pp. 53-55.
Prepublished online as a Blood First Edition Paper on April 10, 2008; DOI 10.1182/blood-2007-11-123950.
 Previous Article | Next Article 
Submitted November 14, 2007
Accepted March 23, 2008
Characteristics and outcome of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
Elias Jabbour, Hagop Kantarjian, Dan Jones, Megan Breeden, Guillermo Garcia-Manero, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, and Jorge Cortes*
Department of Leukemia, U. T. M.D. Anderson Cancer Center, Houston, TX, United States
Department of Hematopathology, U. T. M.D. Anderson Cancer Center, Houston, TX, United States
* Corresponding author; email: jcortes{at}mdanderson.org.
Chronic myeloid leukemia (CML) with T315I mutation has been reported to have poor prognosis. We analyzed 27 patients with T315I including 20 that developed T315I after imatinib failure (representing 11% of 186 patients with imatinib failure), and 7 of 23 who developed new mutations after second tyrosine kinase inhibitor (TKI). Median follow-up from mutation detection was 18 months. At the time of T315I detection, 10 were in chronic (CP), 9 in accelerated, and 8 in blast phase. Except for the lack of response to second TKIs (p=0.002), there was no difference in patient characteristics and outcome between patients with T315I, and those with other or no mutations. Patients in CP had a 2-year survival rate of 87%. Although the T315I mutation is resistant to currently available TKIs, survival of patients with T315I remains mostly dependent on the stage of the disease with many CP patients having an indolent course.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, et al.
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
J. Clin. Oncol.,
December 10, 2009;
27(35):
6041 - 6051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Muller, J. E. Cortes, D.-W. Kim, B. J. Druker, P. Erben, R. Pasquini, S. Branford, T. P. Hughes, J. P. Radich, L. Ploughman, et al.
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Blood,
December 3, 2009;
114(24):
4944 - 4953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Vardiman
Chronic Myelogenous Leukemia, BCR-ABL1+
Am J Clin Pathol,
August 1, 2009;
132(2):
250 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W. Zhang, J. E. Cortes, H. Yao, L. Zhang, N. G. Reddy, E. Jabbour, H. M. Kantarjian, and D. Jones
Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance
J. Clin. Oncol.,
August 1, 2009;
27(22):
3642 - 3649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Jones, S. Kamel-Reid, D. Bahler, H. Dong, K. Elenitoba-Johnson, R. Press, N. Quigley, P. Rothberg, D. Sabath, D. Viswanatha, et al.
Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia: A Report of the Association for Molecular Pathology
J. Mol. Diagn.,
January 1, 2009;
11(1):
4 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, D. Jones, N. Reddy, S. O'Brien, G. Garcia-Manero, J. Burger, and J. Cortes
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
Blood,
December 15, 2008;
112(13):
4839 - 4842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
